FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.
Saved in:
| Title: | FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. |
|---|---|
| Authors: | Antoniotti, Carlotta1,2 (AUTHOR), Marmorino, Federica1,2 (AUTHOR), Rossini, Daniele3 (AUTHOR), Schmoll, Hans Joachim4 (AUTHOR), Lonardi, Sara5 (AUTHOR), Tonini, Giuseppe6,7 (AUTHOR), Borelli, Beatrice1 (AUTHOR), Cupini, Samanta8 (AUTHOR), Stein, Alexander9 (AUTHOR), Moretto, Roberto1 (AUTHOR), Bergamo, Francesca5 (AUTHOR), Ronzoni, Monica10 (AUTHOR), Germani, Marco Maria1,2 (AUTHOR), Zaniboni, Alberto11 (AUTHOR), Fazio, Roberta12 (AUTHOR), De Grandis, Maria Caterina5 (AUTHOR), Ongaro, Elena13 (AUTHOR), Masi, Gianluca1,2 (AUTHOR), Cremolini, Chiara1,2 (AUTHOR) chiaracremolini@gmail.com |
| Source: | European Journal of Cancer. Oct2025, Vol. 228, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09598049 |
|---|---|
| DOI: | 10.1016/j.ejca.2025.115713 |
